Volrustomig  (Synonyms: MEDI-5752)

Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1⁺ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1⁺ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer^[1][2][3][4].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

CTLA4 & PDCD1

Volrustomig potently inhibits CTLA-4 binding on PD-1-positive activated T cells (IC₅₀ 0.01 nmol/L) and is significantly less potent against PD-1-negative T cells (IC₅₀ 4.6 nmol/L)^[4].
Volrustomig provides comparable sustained PD-1 binding and significantly more potent CTLA-4 binding on activated T cells compared to coadministered conventional bivalent anti-PD-1 and anti-CTLA-4 monoclonal antibodies^[4].
Volrustomig (6 hours) induces >90% downregulation of cell surface PD-1 on activated T cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1493  [NCBI] & 5133  [NCBI]

P16410 & Q15116

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.51 kDa

2407760-40-9

Liquid

Colorless to light yellow

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa_VK-CL_3bridges

• 
  Flow Cytometry analysis of Raji cells labelling CTLA4 (red) with Volrustomig (anti-CTLA4) (HY-P990690). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
• 
  Flow Cytometry analysis of THP-1 cells labelling PDCD1 (red) with Volrustomig (anti-PDCD1) (HY-P990690). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Brailey P.M., et al. 288P Volrustomig drives superior CTLA-4 blockade, induces sustained PD-1 degradation, and enhances T cell function ex vivo. Therapeutic Development, 2025, 28(Supplement): 101487.

  [2]. Achour I, et al. Abstract 3627: Volrustomig a novel PD-1/CTLA-4 bispecific antibody leads to robust increase in peripheral and intratumoral pharmacodynamic biomarkers in solid tumors from FTiH study. Cancer Research, 2024, 84(6_Supplement): 3627.

  [3]. Bose CK, et al. Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer. J Gynecol Oncol. 2024;35(4):e82.  [Content Brief]

  [4]. Tran B, et al. Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody. Clin Cancer Res. Published online February 17, 2026.